• Boston Scientific & Symetis

    We are pleased to inform you that Boston Scientific has completed its acquisition of Symetis. As part of this, you may be redirected to the Boston Scientific website on which you will find complete information on the Boston Scientific TAVI Portfolio. We are excited about adding the ACURATE™ Aortic Valve System family of products to our offering and look forward to advancing TAVI by providing the technologies needed to thoughtfully tailor treatment to each patient.

    Boston Scientific & Symetis

latest news

  • 30.03.2017

    Symetis and Boston Scientific reach USD 435 million purchase agreement

    Read more

  • 21.09.2015

    Symetis reaches key milestone: 1000 patients treated with ACURATE neo

    Read more

  • 12.09.2014

    Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations

    Read more

  • 04.03.2014

    Symetis ACURATE TA™ confirms superior results in post-market registry.

    Read more

  • 28.10.2013

    Symetis Announces a Symbolic Milestone: the 1000th Patient implanted with ACURATE TA™.

    Read more   |  Voir le PDF en Français Ansicht PDF in German

  • 26.09.2013

    Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI.

    Read more

Next events

Clinical results

The success of Symetis is due to our strong and continuing investment in R&D and feedback from physicians, during every step of the development process. This philosophy has enabled us to design and manufacture products that truly reflect the requirements of our clinical partners.

ACURATE TA™ CE Mark Trial - Download

The SAVI Registry - Download

ACURATE TF™ FIM - Download

SAVI TF 1000 @ 30 DAYS - Download

ACURATE neo™ - SAVI TF 1000 @ 30 days